Unity Biotechnology (UBX) Competitors

Hookipa Pharma (NASDAQ:HOOK) and Unity Biotechnology (NASDAQ:UBX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.

Is HOOK or UBX more profitable?

Unity Biotechnology has a net margin of 0.00% compared to Hookipa Pharma's net margin of -86.74%. Hookipa Pharma's return on equity of -33.31% beat Unity Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hookipa Pharma	-86.74%	-33.31%	-21.65%
Unity Biotechnology	N/A	-119.70%	-45.86%

Which has stronger earnings and valuation, HOOK or UBX?

Unity Biotechnology has lower revenue, but higher earnings than Hookipa Pharma. Unity Biotechnology is trading at a lower price-to-earnings ratio than Hookipa Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hookipa Pharma	$20.13M	1.51	-$81.58M	-$3.72	-0.68
Unity Biotechnology	$240K	81.28	-$39.86M	-$1.31	-0.88

Do insiders and institutionals hold more shares of HOOK or UBX?

63.9% of Hookipa Pharma shares are held by institutional investors. Comparatively, 29.5% of Unity Biotechnology shares are held by institutional investors. 3.3% of Hookipa Pharma shares are held by insiders. Comparatively, 5.8% of Unity Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has more volatility & risk, HOOK or UBX?

Hookipa Pharma has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Unity Biotechnology has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Does the media prefer HOOK or UBX?

In the previous week, Hookipa Pharma had 6 more articles in the media than Unity Biotechnology. MarketBeat recorded 7 mentions for Hookipa Pharma and 1 mentions for Unity Biotechnology. Unity Biotechnology's average media sentiment score of 0.00 beat Hookipa Pharma's score of -0.19 indicating that Unity Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hookipa Pharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Unity Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts rate HOOK or UBX?

Hookipa Pharma currently has a consensus price target of $38.33, indicating a potential upside of 1,421.16%. Unity Biotechnology has a consensus price target of $8.00, indicating a potential upside of 591.03%. Given Hookipa Pharma's higher possible upside, equities research analysts plainly believe Hookipa Pharma is more favorable than Unity Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Unity Biotechnology	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer HOOK or UBX?

Unity Biotechnology received 84 more outperform votes than Hookipa Pharma when rated by MarketBeat users. However, 70.54% of users gave Hookipa Pharma an outperform vote while only 66.54% of users gave Unity Biotechnology an outperform vote.

Company	Underperform	Outperform
Hookipa Pharma	Outperform Votes 91 70.54%	Underperform Votes 38 29.46%
Unity Biotechnology	Outperform Votes 175 66.54%	Underperform Votes 88 33.46%

Summary

Hookipa Pharma beats Unity Biotechnology on 10 of the 17 factors compared between the two stocks.